Potential for tumor therapy with iodine-125 labeled immunoglobulins

S. J. Adelstein, A. I. Kassis, J. Baranowska-Kortylewicz, A. D. Van Den Abbeele, G. Mariani, S. Ito

Research output: Contribution to journalArticlepeer-review

6 Scopus citations


Because of the high intranuclear toxicity of Auger-electron emitters, the use of radioiodinated (123I, 125I) 5-iodo-2′-deoxyuridine (IUdR)-antibody conjugates for cancer therapy has been examined. The results have demonstrated that all the conditions necessary for labeling DNA in vivo are present: uptake of the radiolabeled immunoglobulin by target cells, its subsequent internalization, the degradation of the IUdR-protein conjugate by lysosomal enzymes, and the incorporation of the radionucleoside into DNA.

Original languageEnglish (US)
Pages (from-to)43-44
Number of pages2
JournalInternational Journal of Radiation Applications and Instrumentation.
Issue number1
StatePublished - 1991
Externally publishedYes

ASJC Scopus subject areas

  • General Medicine


Dive into the research topics of 'Potential for tumor therapy with iodine-125 labeled immunoglobulins'. Together they form a unique fingerprint.

Cite this